Wednesday, June 10, 2026
🇺🇸 FDA

pharma · No medical condition. · Generalized Myasthenia Gravis

Anaxis Pharma

Lacuna Pharma Pty Ltd

Anaxis Pharma clinical programs — 223 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Melbourne, AU HQ
2017 Founded
7 Employees
TGA registrant Type
Company details
Status
Public
HQ
Melbourne, AU
Founded
2017
Employees
7
Programs
642
Drugs
673
Patents
0
Official website ↗ All projects Drug pipeline News & analysis
Intelligence · Clinical Programs

Anaxis Pharma projects

223 ClinicalTrials.gov programs sponsored by Anaxis Pharma.

Anaxis Pharma has 223 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

223 programs

Clinical programs

Page 4 of 5

  1. Placebo for ACP-204 capsules

    Lacuna Pharma Pty Ltd

    Lewy Body Dementia Psychosis (LBDP)

    phase 2 small molecule active

    1 trial

  2. Placebo to match ACP-204

    Lacuna Pharma Pty Ltd

    Alzheimer Disease psychosis

    phase 2 small molecule active

    1 trial

  3. Placebo to match IMP TEV-56286, Emrusolmin

    Lacuna Pharma Pty Ltd

    Multiple System Atrophy

    phase 2 small molecule active

    1 trial

  4. PolyCore

    Lacuna Pharma Pty Ltd

    End-Stage Kidney Disease

    phase 2 small molecule active

    1 trial

  5. QINLOCK 50 mg tablets

    Lacuna Pharma Pty Ltd

    Advanced gastrointestinal stromal tumor (GIST)

    phase 2 small molecule active

    1 trial

  6. R10597-ONC-22114

    Lacuna Pharma Pty Ltd

    Melanoma, Advanced Solid Tumours, Clear-Cell Renal-Cell Carcinoma (ccRCC)

    phase 2 small molecule active

    1 trial

  7. R13335-PAH-2365

    Lacuna Pharma Pty Ltd

    Pulmonary Arterial Hypertension (PAH)

    phase 2 small molecule active

    1 trial

  8. R1979-ONC-1625

    Lacuna Pharma Pty Ltd

    B-cell non-Hodgkin lymphoma (NHL)

    phase 2 small molecule active

    1 trial

  9. R2810-ONC-2045

    Lacuna Pharma Pty Ltd

    Advanced Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  10. R2810-ONC-2268

    Lacuna Pharma Pty Ltd

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  11. R3767-ONC-2208

    Lacuna Pharma Pty Ltd

    Melanoma

    phase 2 small molecule active

    1 trial

  12. R3767-ONC-2266

    Lacuna Pharma Pty Ltd

    Resectable Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  13. R3767-ONC-2466

    Lacuna Pharma Pty Ltd

    Melanoma

    phase 2 small molecule active

    1 trial

  14. R4018-ONC-1721

    Lacuna Pharma Pty Ltd

    Fallopian Tube Cancer, Endometrial Cancer, Ovarian Cancer, Primary Peritoneal Cancer

    phase 2 small molecule active

    1 trial

  15. R5458-ONC-1826

    Lacuna Pharma Pty Ltd

    Relapsed or Refractory Multiple Myeloma

    phase 2 small molecule active

    1 trial

  16. R5458-ONC-2257

    Lacuna Pharma Pty Ltd

    High-Risk Monoclonal Gammopathy of Undetermined Significance; Non-High-Risk Smoldering Multiple Myeloma

    phase 2 small molecule active

    1 trial

  17. R5458-ONC-2274

    Lacuna Pharma Pty Ltd

    Relapsed or Refractory Systemic Light Chain Amyloidosis

    phase 2 small molecule active

    1 trial

  18. R7508-DVT-2360

    Lacuna Pharma Pty Ltd

    Thromboembolic disease

    phase 2 small molecule active

    1 trial

  19. R7999 matching placebo, REGN7999

    Lacuna Pharma Pty Ltd

    Non-transfusion dependent beta-thalassemia (NTDT), Beta-thalassemia Resultant Iron overload (IOL)

    phase 2 small molecule active

    1 trial

  20. R9933-DVT-2308

    Lacuna Pharma Pty Ltd

    Venous Thromboembolism

    phase 2 small molecule active

    1 trial

  21. RC02T001

    Lacuna Pharma Pty Ltd

    Mixed Dyslipidemia

    phase 2 small molecule active

    1 trial

  22. RC03T001

    Lacuna Pharma Pty Ltd

    Stable Coronary Artery Disease

    phase 2 small molecule active

    1 trial

  23. RC04T001

    Lacuna Pharma Pty Ltd

    Chronic hepatitis D virus infection

    phase 2 small molecule active

    1 trial

  24. REGN5093

    Lacuna Pharma Pty Ltd

    MET-altered non-small cell lung cancer (NSCLC)

    phase 2 small molecule active

    1 trial

  25. REGN7041

    Lacuna Pharma Pty Ltd

    Noninfectious Uveitis

    phase 2 small molecule active

    1 trial

  26. REGN7257

    Lacuna Pharma Pty Ltd

    Severe aplastic anemia (SAA)

    phase 2 small molecule active

    1 trial

  27. REGN7544, REGN7544 Matching Placebo

    Lacuna Pharma Pty Ltd

    Sepsis-Induced Hypotension

    phase 2 small molecule active

    1 trial

  28. REGV131, LNP1265

    Lacuna Pharma Pty Ltd

    Hemophilia B

    phase 2 small molecule active

    1 trial

  29. RP-A501-0123

    Lacuna Pharma Pty Ltd

    Danon Disease

    phase 2 small molecule active

    1 trial

  30. RPL554-NCFB-220

    Lacuna Pharma Pty Ltd

    Non-Cystic Fibrosis Bronchiectasis

    phase 2 small molecule active

    1 trial

  31. RTP-026 Placebo, RTP-026

    Lacuna Pharma Pty Ltd

    Patients with ST-Elevation Myocardial Infarction (STEMI)

    phase 2 small molecule active

    1 trial

  32. Rilzabrutinib

    Lacuna Pharma Pty Ltd

    Immune Thrombocytopenia

    phase 2 small molecule active

    1 trial

  33. SCD-044-19-14

    Lacuna Pharma Pty Ltd

    moderate to severe plaque psoriasis

    phase 2 small molecule active

    1 trial

  34. SCD-044-19-16

    Lacuna Pharma Pty Ltd

    atopic dermatitis

    phase 2 small molecule active

    1 trial

  35. SIROLIMUS, SIROLIMUS

    Lacuna Pharma Pty Ltd

    Subjects diagnosed with port wine stains

    phase 2 small molecule active

    1 trial

  36. SKB264-II-04

    Lacuna Pharma Pty Ltd

    Advanced or Metastatic Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  37. SNOXA12C401

    Lacuna Pharma Pty Ltd

    Glioblastoma

    phase 2 small molecule active

    1 trial

  38. SODIUM CHLORIDE

    Lacuna Pharma Pty Ltd

    Idiopathic Pulmonary Fibrosis

    phase 2 small molecule active

    1 trial

  39. SODIUM CHLORIDE SOLUTION 0.9%

    Lacuna Pharma Pty Ltd

    Acute Ischemic Stroke

    phase 2 small molecule active

    1 trial

  40. SP-GL0034-02

    Lacuna Pharma Pty Ltd

    Type 2 diabetes mellitus

    phase 2 small molecule active

    1 trial

  41. SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor

    Lacuna Pharma Pty Ltd

    Hypercortisolism related to benign adrenal tumour

    phase 2 other active

    1 trial

  42. SPI-62-CL-2003

    Lacuna Pharma Pty Ltd

    Polymyalgia rheumatica (PMR)

    phase 2 small molecule active

    1 trial

  43. SPI-62_DF2

    Lacuna Pharma Pty Ltd

    Cushing's Syndrome

    phase 2 small molecule active

    1 trial

  44. SY-1425, AZACITIDINE

    Lacuna Pharma Pty Ltd

    Acute Myeloid Leukemia (AML) Myelodysplastic Syndrome (MDS)

    phase 2 small molecule active

    1 trial

  45. SY-1425-202

    Lacuna Pharma Pty Ltd

    RARA-positive acute myeloid leukemia

    phase 2 small molecule active

    1 trial

  46. Sodium chloride Fresenius Kabi 0 for Cerebral Autosomal Dominant Art…

    Lacuna Pharma Pty Ltd

    Cerebral Autosomal Dominant Arteriopathy with subcortical Infarcts and Leukoencephalopathy (CADASIL)

    phase 2 small molecule active

    1 trial

  47. Sunvozertinib, Sunvozertinib

    Lacuna Pharma Pty Ltd

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  48. SynAct-CS003

    Lacuna Pharma Pty Ltd

    Idiopathic membranous nephropathy and severe proteinuria

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Anaxis Pharma have?

223 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.